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Abstract
Oxidative stress is considered to be involved in the pathophysiology of all cancers. In order to
evaluate the total oxidant/antioxidant status in patients with thyroid cancer and to investigate the
relationship between oxidative stress parametersand serum thyroid proﬁlesamong thyroidcancer
patients and various controls, we determined oxidative status including total antioxidant status
(TAS) and total oxidant status (TOS) and calculation of oxidative stress index (OSI) in sera in 82
thyroid cancer patients, 56 benign thyroid disease patients, and 50 healthy controls. It was found
that serum TAS levels were signiﬁcantly lower in patients with thyroid cancer than in controls
(P!0.001),whileserumTOSlevelsandOSIvaluesweresigniﬁcantlyhigher(bothP!0.001)inthe
cancer patients. No signiﬁcant correlations were observed between various oxidative stress
markersandthyroidproﬁlesineitherthethyroidcancerpatientsorthecontrols.Receiveroperating
characteristiccurveanalysisdemonstratedthatOSIwasthebestindicatorfordistinguishingcancer
patientsfrombenignthyroiddiseasedorhealthycontrols,followedbyTOSandTAS.Riskestimate
statistics also indicated that TOS and/or OSI were good risk factors to discriminate patients with
thyroid cancer from two controls. These ﬁndings suggested that oxidants are increased and
antioxidants are decreased in patients with thyroid cancer. OSI may be a more useful oxidative
stress biomarker than TAS and TOS for monitoring the clinical status of thyroid cancer patients.
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Introduction
Thyroid cancer is the most common endocrine
malignancy and its incidence continues to rise yearly.
Thyroid carcinoma, in most cases, presents clinically
as a solitary nodule or as a dominant nodule within a
multinodular thyroid gland. The challenge to clinicians
is to discriminate between the minority of thyroid
nodules (5–15%) that harbor malignancies and the
majority of cases that can be managed conservatively
(Boelaert 2009). Thus, it is very important to identify
one or more markers to distinguish thyroid cancer from
different types of thyroid disease.
Cellular oxidative damage is a well-established
general mechanism of cell and tissue injury that is
primarily caused by free radicals and reactive oxygen
species (ROS). Low levels of ROS are indispensable
in many biochemical processes (Valko et al. 2007);
however, overproduction and/or inadequate removal
of ROS can result in oxidative stress, which is
characterized as an imbalance between the formation
of active oxygen metabolites and the rate at which they
are scavenged by enzymatic and non-enzymatic
antioxidants. Oxidative stress can participate in the
pathogenesis and complications of many diseases
(including cancer; Uttara et al. 2009).
Thyroid hormones regulate oxidative metabolism and
thus play an important role in free radical production
(Erdamar et al.2 0 0 8 ). Thyroid hormones regulate the
synthesis and degradation of enzymes, such as super-
oxidedismutase(SOD),catalase,glutathioneperoxidase
(GPx), and glutathione reductase, and non-enzymatic
antioxidants, such as vitamin E and C, glutathione, uric
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edly, the changes in these enzymes and non-enzymatic
substances affect the redox balance in the body and, in
turn,enzymaticfeedbackregulatesthyroidfunction.One
of the major effects of thyroid hormones is to increase
mitochondrial respiration, which results in upregulation
ofROS,leadingtooxidativedamagetomembranelipids
(Erdamar et al.2 0 0 8 ).
Inrecentyears,interesthas grown instudyingthe role
played by oxidative stress in thyroid carcinogenesis by
investigating one or more of the antioxidant markers,
including SOD (Laatikainen et al.2 0 1 0 , Lassoued et al.
2010, Erdamar et al.2 0 1 0 ), catalase (Lassoued et al.
2010), GPx (Lassoued et al.2 0 1 0 , Erdamar et al.2 0 1 0 ),
vitamin E (Alkhenizan and Hafez 2007), vitamin C
(Liuetal.2010),glutathione(Duetal.2009),and/oruric
acid (Abiaka et al.2 0 0 1 ). However, the measurement of
different antioxidant molecules separately was not only
impractical but also held no clinical signiﬁcance.
Because the effects of antioxidants can be additive and
measuring individual antioxidants separately is time
consuming and labor intensive, a measurement of the
combined activities of all antioxidants or the total
antioxidant status (TAS) is often used to estimate the
overall antioxidative status (Erel 2004). Likewise, total
oxidantstatus(TOS)ismeasuredtodetermineapatient’s
overall oxidation state (Erel 2005). Furthermore,
the oxidative stress index (OSI), which is calculated as
the ratio of TOS to TAS, may be a more accurate index
of oxidative stress in the body because it is a
comprehensive measurement of TAS and TOS.
Oxidative stress is common in the thyroid tissue
during utilization of H2O2 for thyroxine (T4) synthesis,
the inﬂammation produces ROS, and when tumor has
active proliferation (Akinci et al. 2008). Therefore,
oxidative stress has been reported to be consistently
associated with hyperthyroidism or hypothyroidism
(Erdamar et al. 2008). However, to date, our under-
standing of the roles of the oxidative/antioxidative
systems in the carcinogenesis of thyroid cancer and
their relationships to thyroid proﬁles is limited. To
address this, we evaluated the levels of TAS, TOS, and
OSI in thyroid cancer patients, benign thyroid disease
patients, and healthy controls and analyzed the
relationship among these oxidative stress parameters,
thyroid proﬁles, and thyroid cancer.
Materials and methods
Subjects
From March 2005 to December 2010, 82 patients
with thyroid cancer (35 males and 47 females) were
involved in this study. All patients were newly
diagnosed as having thyroid cancer based on clinical
laboratory investigations conﬁrmed by ﬁne needle
aspiration. The mean age of the patients was 33.4G7.9
years with a range of 12–53 years. Of these 82
cancer patients (cancer group), there were 53 papillary
thyroid cancer (PTC) patients, 18 follicular thyroid
cancer patients, six anaplastic differentiated
thyroid cancer (ATC) patients, and ﬁve medullary
thyroid cancer patients. In addition, there were 56
benign thyroid disease patients (22 males and 34
females; age range 15–62 years) that served as disease
controls, including 36 patients with hyperthyroidism
due to Graves’ disease (hyperthyroidism group) and
20 patients with hypothyroidism due to Hashimoto’s
thyroiditis (hypothyroidism group). These patients
were also newly diagnosed cases of clinical
dysthyroidism.
Age-matched subjects from the same region (nZ50;
19 males and 31 females; age range 17–56 years)
were used as healthy controls (healthy group (HG)).
HG blood samples were measured in parallel to obtain
normal base line values.
The study protocol was approved by the Medical
Ethics Committee of Mianyang Central Hospital,
Sichuan province, China, and written informed
consent was obtained from all legal guardians of tested
participants.
Blood samples
After overnight fasting, blood was drawn by veni-
puncture at the antecubital vein from the subjects
between 0730 and 1000 h. Approximately 5 ml blood
was collected into a BD Vacutainer SST II ADVANCE
tube (Becton Dickinson, Rutherford, NJ, USA) for
analysis of oxidative stress markers and thyroid
proﬁles. After 1 h, blood samples were centrifuged
at 700 g for 15 min, and sera samples were collected
and stored at K30 8C until analysis within 48 h.
Thyroid proﬁles
Thyroid proﬁles were assessed by estimation of
serum-free triiodothyronine (FT3), free T4 (FT4),
and thyrotropic-stimulating hormone (TSH), which
were assayed by a chemiluminescent assay method
using a LIAISON analyzer with original kits
obtained from DiaSorin (DiaSorin S.p.A, Saluggia,
Italy). The FT3 to FT4 ratio (FT3/FT4) was also
calculated.
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TAS was measured colorimetrically using the TAS
kit (Eurobiomed Randox, London, UK). This assay
relies on the ability of antioxidants in the sample to
inhibit the formation of ABTS
C from oxidation of
ABTS (2.20-azino-di-(3-ethylbenz-thiazoline sulfo-
nate)) by metmyoglobin (a peroxidase). An antioxidant
of known concentration (1.65 mmol/l) was used as a
standard for the calculation of antioxidant levels in the
samples. Values of TAS were expressed as mmol
Trolox equivalent/l (mmol Trolox equiv./l).
TOS determination
Serum TOS was measured using Erel’s TOS method
(Harma et al. 2005), which is based on the oxidation of
ferrous ion to ferric ion in the presence of various
oxidative species in acidic medium and the measure-
ment of the ferric ion by xylenol orange. The test
parameters were as follows: end-point measurement,
serum 10 ml, R1 200 ml, R2 50 ml, 10 min at 37 8C, read
points 34, primary wavelength 560 nm, and secondary
wavelength 800 nm. The results were expressed in
mmol H2O2 equivalent/l (mmol H2O2 equiv./l).
Oxidative stress index
The TOS to TAS ratio was regarded as the OSI
(Aycicek et al. 2005, Harma et al. 2005) and was
calculated as follows: OSI (arbitrary unit)Z((TOS,
mmol H2O2 equiv./l)/(TAS, mmol Trolox equiv./l)!
100) (Aycicek & Erel 2007).
Statistical analysis
All data were expressed as the meanGS.D. and/or range
(minimum–maximum). One-way ANOVA was used
to determine the signiﬁcance of biochemical para-
meters among the study groups. The least signiﬁcant
difference test was used for multiple comparisons to
estimate the difference between the two study groups.
Multiple linear regression analysis was performed to
evaluate the associations between serum levels of
oxidative stress markers and thyroid proﬁles. Receiver
operating characteristic (ROC) curves, depicting the
ability to discriminate between controls and malignant
conditions, were plotted for the oxidative stress
markers and reported the area under the curve (AUC)
and its 95% conﬁdence interval (CI). P values !0.05
were considered statistically signiﬁcant. All statistical
analyses were carried out using the statistical
package program version SSPS 17.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
In this study, hyperthyroidism was deﬁned as a basal
serum TSH !0.4 mIU/l, FT4 O1.9 ng/ml, and FT3
O4.2 pg/ml. Hypothyroidsm was deﬁned as basal
serum TSH O4.0 mIU/l, FT4 !0.8 ng/ml, and FT3
!1.8 pg/ml. Healthy controls included demonstrated a
basal serum TSH 0.4–3.8 mIU/l, FT4 0.8–1.7 ng/ml,
and FT3 2.2–4.2 pg/ml.
The results are expressed as meanGS.D.w i t h
minimum and maximum values shown in Table 1.
Samples of various concentrations were assayed to
estimate repeatability and reproducibility of each
Table 1 Serum levels of oxidative stress markers and thyroid proﬁles in study groups (above: meanGS.D., below: min.–max.)
Items CG (82) HpeG (36) HpoG (20) HG (50) Statistic values
TAS 1.37G0.20*
,‡,§ 1.52G0.13
† 1.53G0.11
† 1.67G0.15 FZ32.951
1.00–1.70 1.33–1.77 1.32–1.69 1.45–1.95 PZ0.000
TOS 21.34G2.82*
,‡,§ 15.79G1.41
† 16.08G1.47
† 14.87G1.01 FZ129.850
16.23–26.55 13.51–18.82 13.35–18.08 13.22–16.95 PZ0.000
OSI 1.60G0.31*
,‡,§ 1.05G0.11
† 1.06G0.11
† 0.89G0.07 FZ129.069
1.01–2.33 0.82–1.23 0.91–1.28 0.69–1.09 PZ0.000
TSH 0.221G0.354*
,§ 0.028G0.027* 20.665G4.054* 1.627G0.766 FZ1269.993
0.002–2.075 0.004–0.088 15.908–29.664 0.677–3.050 PZ0.000
FT3 2.82G0.59*
,§ 7.16G1.40* 1.42G0.37* 3.02G0.42 FZ351.354
1.52–4.19 5.45–9.70 0.95–1.95 2.25–3.95 PZ0.000
FT4 1.10G0.31
‡ 15.76G6.62* 0.53G0.16 1.22G0.24 FZ249.572
0.53–1.69 5.62–28.12 0.30–0.82 0.82–1.67 PZ0.000
FT3/FT4 2.80G1.05
‡ 0.57G0.32* 2.98G1.39
† 2.56G0.53 FZ60.484
0.90–5.46 0.21–1.50 1.45–6.23 1.42–3.80 PZ0.000
Comparison with HG, *P!0.001,
†P!0.05; comparison with HpeG,
‡P!0.001; comparison with HpoG,
§P!0.001. Least signiﬁcant
difference(LSD) test. TAS,TOS, and OSI units are expressed asmmol Trolox equivalent/l, mmol H2O2 equivalent/l, and arbitrary unit
respectively. CG, cancer group; HpeG, hyperthyroidism group; HpoG, hypothyroidism group; HG, healthy group.
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variation (CVi, CVd) are presented in Table 2.
One-way ANOVA showed (Table 1) signiﬁcant
differences among the study groups in the levels of
oxidative stress markers TAS (FZ16.958, PZ0.000),
TOS (FZ55.796, PZ0.000), and OSI (FZ56.419,
PZ0.000), as well as thyroid proﬁle TSH (FZ
813.033, PZ0.000), FT3 (FZ86.239, PZ0.000), FT4
(FZ191.500, PZ0.000), and FT3/FT4 (FZ37.327,
PZ0.000). These results indicated increased oxidative
stress in both thyroid disease patients and thyroid
cancer patients. However, no statistically signiﬁcant
differences were found in serum TAS, TOS, and OSI
values among carcinoma histological subtypes
(Table 3).
Multiple linear regression analysis were performed
with the TAS, TOS, or OSI as dependent variables
and using TSH, FT3,F T 4, and FT3/FT4 as independent
variables. The results showed no signiﬁcant corre-
lations between various oxidative stress markers and
thyroid proﬁles for either the thyroid cancer patients
or the controls (Table 4).
ROC curves for the abilities of TAS, TOS, and OSI
to distinguish between benign and malignant diagnoses
are plotted in Fig. 1A–D respectively. Based on the
results from the ROC curve analysis, the optimal cutoff
Table 2 Estimation of the repeatability and reproducibility of each assay
Intra-assay Day-to-day
Mean n CVi (%) Mean n CVd (%)
TAS (mmol Trolox equiv./l) 0.92 20 1.75 0.93 20 3.13
1.26 20 1.22 1.30 20 3.46
1.90 20 1.79 2.03 20 2.87
TOS (mmol H2O2 equiv./l) 13.06 20 2.01 13.22 20 2.76
16.88 20 1.89 18.72 20 2.53
26.43 20 1.91 26.19 20 2.56
FT3 (pg/ml) 1.01 20 4.6 1.96 20 6.3
2.01 20 2.8 3.64 20 4.2
3.80 20 1.7 9.79 20 2.9
13.80 20 1.4 13.05 20 3.9
FT4 (ng/dl) 0.39 20 2.4 0.48 23 4.8
0.90 20 1.6 0.90 31 3.7
1.47 20 1.1 1.53 32 2.9
3.00 20 2.4 3.02 31 3.3
6.36 20 2.0 6.36 30 3.2
TSH (mIU/l) 0.17 20 1.9 0.17 21 5.1
10.4 20 0.7 10.5 21 1.6
36.1 20 0.9 36.8 21 2.2
Table 3 Serum levels of oxidative stress markers in carcinoma histological subtypes
Items Cancer (n) Mean S.D. Min. Max. Statistic values
TAS PTC (53) 1.38 0.20 1.04 1.70 FZ0.430, PZ0.732
FTC (18) 1.35 0.22 1.00 1.63
ATC (6) 1.33 0.15 1.05 1.46
MTC (5) 1.29 0.25 1.04 1.56
TTC (82) 1.37 0.20 1.00 1.70
TOS PTC (53) 21.81 2.86 17.18 26.55 FZ1.627, PZ0.190
FTC (18) 20.80 2.60 16.23 23.96
ATC (6) 20.11 2.49 16.71 23.06
MTC (5) 19.78 3.01 16.59 22.81
TTC (82) 21.34 2.82 16.23 26.55
OSI PTC (53) 1.61 0.31 1.14 2.33 FZ0.190, PZ0.903
FTC (18) 1.59 0.37 1.01 2.33
ATC (6) 1.52 0.17 1.29 1.78
MTC (5) 1.56 0.20 1.31 1.86
TTC (82) 1.60 0.31 1.01 2.33
PTC, papillary thyroid cancer; FTC, follicular thyroid cancer patients; ATC, anaplastic differentiated thyroid cancer; MTC, medullary
thyroid cancer; TTC, total thyroid cancer.
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the Youden index (YI). AUC, cutoff values, sensitivity,
speciﬁcity, and YI are reported in Table 5. The results
showed that the OSI was the best indicator for
distinguishing cancer patients from disease controls
and/or healthy controls, followed by TOS and TAS.
Compared with disease controls, AUC (95% CI) was
0.964 (0.933–0.994) for OSI, 0.929 (0.883–0.974) for
TOS, and 0.702 (0.599–0.805) for TAS. Compared
with healthy controls, AUC (95% CI) was 1.000
(1.000–1.000) for OSI, 0.996 (0.000–1.000) for TOS,
and 0.878 (0.803–0.954) for TAS. Between disease
controls and healthy controls, the AUC (95% CI)
was 0.979 (0.960–0.998) for OSI, 0.957 (0.928–0.986)
for TOS, and 0.776 (0.697–0.855) for TAS. These
data show that lower TAS and higher TOS levels
(i.e. increased oxidative stress) may be related to
thyroid cancer.
Table 4 Association between various oxidative stress markers and thyroid proﬁles by multiple linear regression analysis
n TSH (r, P) FT3 (r, P) FT4 (r, P) FT3/FT4 (r, P) RF , P
TAS 50 K0.046, 0.376 0.034, 0.408 0.104, 0.237 K0.090, 0.267 0.142 0.230, 0.920
56 0.073, 0.297 0.011, 0.469 K0.011, 0.467 0.082, 0.274 0.196 0.511, 0.827
82 K0.031, 0.391 0.106, 0.172 K0.057, 0.307 0.081, 0.234 0.127 0.315, 0.867
TOS 50 K0.004, 0.488 K0.043, 0.385 0.096, 0.254 K0.128, 0.188 0.149 0.255, 0.905
56 0.114, 0.201 K0.093, 0.248 0.069, 0.307 K0.015, 0.456 0.302 1.282, 0.289
82 K0.036, 0.376 0.132, 0.118 K0.170, 0.063 0.49, 0.090 0.275 1.578, 0.189
OSI 50 0.069, 0.316 K0.054, 0.356 K0.034, 0.408 0.005, 0.486 0.104 0.122, 0.974
56 0.032, 0.407 K0.078, 0.283 0.071, 0.301 K0.084, 0.270 0.247 0.829, 0.513
82 K0.002, 0.493 K0.012, 0.458 K0.049, 0.330 0.008, 0.471 0.100 0.194, 0.941
r, Pearson’s correlation coefﬁcient; R, multiple correlation coefﬁcient.
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Figure 1 ROCcurveanalysesoftheoxidativestressbiomarkers.(A)(HpeGCHpoG)vsCG;(B)HGvsCG;(C)(HGCHpeGCHpoG)
vs CG; (D) HG vs (HpeGCHpoG). The TAS curve is inverted because the results are decreased.
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cutoff values obtained by ROC curve analysis. These
results showed that the TOS and/or TOS were
sufﬁcient risk factors to discriminate thyroid cancer
from benign thyroid diseases and/or healthy controls
(Table 6).
Discussion
Aerobic organisms have developed complex anti-
oxidant systems that can counteract ROS and free
radicals. This system can prevent and/or reduce ROS-
and free radical-induced oxidative damage to tissues
and cells (Wells et al. 2009) and is composed of
different antioxidant substances, including the
enzymes, nonenzymatic antioxidants, and an array of
small molecules (Santi et al. 2010). These known
and many unknown antioxidant substances compose
the body’s complex antioxidant system. To assess the
antioxidant status in vivo, it is essential to measure the
levels of overall antioxidants, including those known
and unknown. In addition, the dynamic distribution of
different antioxidants in various biological samples and
their potential interactions make it difﬁcult to measure
each antioxidant separately, and such measurements
are also unlikely to represent the overall antioxidant
substances in the body. Similarly, to assess the oxidant
status in vivo, it is essential to measure the levels of
overall oxidants.
However, in previous studies concerning the role of
antioxidants in thyroid cancer, most reports measured
only one or several antioxidant substances separately
(Senthil & Manoharan 2004, Akinci et al. 2008, Lin
et al. 2009, Laatikainen et al. 2010, Young et al. 2010)
such that the results did not reﬂect the total anti-
oxidant levels in patients. In the current study, we
recommended measuring the total oxidant/antioxidant
status of an organism. Owing to the various
interactions among antioxidants and oxidants, we
believe that by measuring the total effects of the
oxidants/antioxidants present in an organism, we can
obtain more valuable results. Many previous studies
have revealed increased oxidative stress in thyroid
cancer (Abiaka et al. 2001, Senthil & Manoharan 2004,
Alkhenizan and Hafez 2007, Akinci et al.2 0 0 8 , Du
et al. 2009, Lin et al. 2009, Laatikainen et al. 2010,
Lassoued et al. 2010, Erdamar et al. 2010, Liu et al.
2010, Young et al. 2010). Thus, in our study, in
addition to the TAS, we measured serum TOS levels
and calculated OSI values. One-way ANOVA showed
signiﬁcant differences among studygroups in the levels
of TAS and TOS. However, no statistically signiﬁcant
differences were found in serum TAS, TOS, and OSI
values among carcinoma histological subtypes. The
OSI reﬂects the redox balance between oxidation and
antioxidation in a subject in vivo. Our results showed
that OSI values were decreased in thyroid disease
patients, indicating that in these participants, the redox
balance capability was poor and therefore oxidative
stress was inevitable. Thus, OSI levels were lower in
patients with thyroid cancer than in those with benign
thyroid disease, which were in turn lower than those in
the healthy subjects.
Table 5 Performance of oxidative stress markers in predicting thyroid cancer
AUC (95% CI) Cutoff Se Sp YI
(HpeGCHpoG)vs CG
TAS 0.706 (0.620–0.792) 1.41 85.7 48.8 0.345
TOS 0.963 (0.938–0.989) 17.17 92.7 85.7 0.784
OSI 0.975 (0.954–0.997) 1.21 90.2 94.6 0.848
HG vs CG
TAS 0.862 (0.801–0.923) 1.56 74.0 84.1 0.581
TOS 0.998 (0.000–1.000) 16.54 97.6 98.0 0.956
OSI 0.999 (0.000–1.000) 1.11 98.8 100.0 0.988
(HGCHpeGCHpoG) vs CG
TAS 0.780 (0.715–0.845) 1.41 92.5 48.8 0.413
TOS 0.980 (0.965–0.994) 16.69 96.3 84.9 0.812
OSI 0.987 (0.974–0.999) 1.19 91.5 96.2 0.877
HG vs (HpeGCHpoG)
TAS 0.750 (0.659–0.841) 1.56 74.0 84.1 0.581
TOS 0.734 (0.639–0.829) 16.83 57.1 84.0 0.411
OSI 0.871 (0.803–0.939) 0.99 71.4 92.0 0.634
TAS,TOS,andOSIunitsareexpressedasmmolTroloxequiv./l,mmolH2O2equiv./l,andarbitraryunitrespectively.Se,sensitivity;Sp,
speciﬁcity; YI, Youden index; CG, cancer group; HpeG, hyperthyroidism group; HpoG, hypothyroidism group; HG, healthy group.
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and antioxidative status of an organism and thus
play an important role in ROS and free radical
production (Coria et al. 2009, Erdamar et al. 2010).
In the thyroid, ROS and free radicals participate in
physiological and pathological processes so that redox
imbalance (Senthil & Manoharan 2004, Akinci et al.
2008, Laatikainen et al. 2010, Young et al. 2010).
Antioxidative defense pathways of the organism play
a crucial role in reducing the increased levels of
free radicals generated by thyroid gland dysfunction
(Carmeli et al. 2008). In hyperthyroidism, there is
augmented production of ROS because the basal
metabolic rate is increased, which in the presence
of inadequate antioxidative defense results in the
occurrence of oxidative stress in these patients
(Saad-Hussein et al. 2011). In hypothyroidism, the
basal metabolic rate is decreased and therefore a
decrease in free radical production is expected because
of the metabolic suppression caused by the lowered
thyroid hormone levels (Erdamar et al. 2008). In
thyroid cancer, cancerous thyroid tissues have accel-
erated lipid peroxidation and diminished antioxidant
scavenging enzymes, leaving these tissues more
vulnerable to the toxic effects of some free radical
species (Erdamar et al. 2010). Our study, however,
demonstrated no signiﬁcant correlations between
various oxidative stress markers and thyroid proﬁles
using multiple linear regression analysis (Table 3).
These results suggested that no direct association or
not a linear relationship in serum between variations of
the levels of thyroid hormones and redox imbalance
were caused by thyroid gland dysfunction, although
the thyroid hormone can regulate oxidative
metabolism and affect enzymatic antioxidants such as
SOD catalase, GPx, and glutathione reductase levels
and non-enzymatic antioxidants such as vitamin E
and C, glutathione, and uric acid levels in vivo.
Possible explanations for this phenomenon include
1) a rigorous and complex antioxidant defense system
in the body, 2) the impact on radical chain reactions
(accelerated or delayed) by the altered levels of
oxidants/antioxidants, 3) the partial effect on oxidant/
antioxidants that are subject to change, or 4) other
unknown causes to be investigated.
A previous study conﬁrmed that markers of
oxidative stress can be divided into three categories:
1) the formation of modiﬁed molecules by free radical
reactions, 2) the consumption or induction of anti-
oxidant molecules or enzymes, and 3) the activation or
inhibition of transcription factors (Erdamar et al.2 0 1 0 ).
The category of oxidative stress markers most likely
to change when thyroid function is abnormal requires
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www.endocrinology-journals.org 779further study. However, should we need to explore what
kind of antioxidants level is decreased? It is worth
considering. To simply understand the oxidative stress
status of patients, it is sufﬁcient to measure the TAS and
TOS and calculate the OSI. However, concerning
the study of oxidative stress for thyroid cancer patients
and/or benign thyroid disease patients, most researchers
onlydeterminedtheTAS(Mayeretal.2004,Bacic-Vrca
et al.2 0 0 5 , Andryskowski & Owczarek 2007, Ish-
Shalom et al.2 0 0 8 , Torun et al.2 0 0 9 ), some also
determined the TOS (Santi et al.2 0 1 0 , Aslan et al.
2011), and very few studies also calculated the OSI
(Aslan et al.2 0 1 1 ) values. However, the TAS had the
least accuracy (both AUC and YI are minimal) in our
studyforthedifferentialdiagnosisofthyroidcancerfrom
disease controls and/or healthy controls (Table 4 and
Fig. 1). ROC analysis revealed that a perfect test would
have an AUC of 1.000, sensitivity of 100%, a speciﬁcity
of100%,andaYIof1.000atacutoffvalueof1.01OSIto
distinguish thyroid cancer patients from the healthy
populationwhile bothAUCandYIare maximalinother
statistic groups (Table 4). These results suggest that the
OSI may be a good candidate marker for distinguishing
thyroid cancer from disease controls and/or healthy
controls. Therefore, to obtain a comprehensive under-
standing of the oxidative stress status of a subject, we
should not only measure the TAS and TOS but also
calculate the OSI. It can be speculated that TAS is not
practiced widely by researchers and clinicians because
it reﬂects the oxidative stress with one-sidedness, i.e.
the speciﬁcity is lower. Risk estimate statistics have
shownthatbothTOSandOSIwerebetterindicatorsthan
TAS either for discriminating thyroid cancer from
controls (including disease and healthy controls) or for
discriminating thyroid disease from healthy controls
(Table 5). This result demonstrated once again that if
we wanttofully understand the oxidative stressstatusof
patients in vivo, not only TAS and TOS measurements
but also the calculation of OSI are necessary.
Recently, one of the focuses on the molecular
pathogenesis of thyroid cancer is BRAFV600E
mutation. BRAFV600E is a constitutively active
onco-kinase and is the most common genetic alteration
in PTC and ATC, albeit at a lower frequency (Nucera
et al.2 0 1 1 ). BRAFV600E through the mitogen-
activated protein kinase signaling pathway may
control a network of genes crucial in integrating and
regulating the extracellular and intracellular signaling
in thyroid cancer cells. The BRAFV600E mutation in
some studies has been signiﬁcantly associated with
extra-thyroidal extension, metastases, and recurrence
in patients with PTC and ATC (Nucera et al. 2010).
Recent investigations have suggested that oxidative
stress caused by inﬂammation may be in part
responsible for mutations of the BRAF gene (Martinez-
Cadenas et al.2 0 1 1 ). Other authors also found that
oxidative stress plays a critical role in inactivating
mutant BRAF by geldanamycin derivatives (Fukuyo
et al. 2008). These ﬁndings are similar to those of this
study. However, the exact mechanism of BRAFV600E
mutation induced by oxidative stress needs to explore.
Collecting tissue samples can cause injury, and
the pre-analytical specimen treatment is complicated.
Furthermore, it is difﬁcult to develop the appropriate
reference range, and the results may only reﬂect the
local tissue levels in patients. In contrast, collecting
blood samples can overcome these limitations. There-
fore, we chose to use blood samples for the current
study not only to facilitate scientiﬁc research but also
to pave the way for future clinical application.
In this study, our observations suggest that the serum
TOS and OSI values were higher and TAS levels were
lower in patients with thyroid cancer than in controls.
There were no correlations between thyroid proﬁles
and oxidative/antioxidative parameters. Therefore,
increased levels of oxidants and decreased levels
of antioxidants may provide evidence for thyroid
patients who were exposed to potent oxidative stress.
OSI values may be more useful oxidative stress
biomarkers than TAS and TOS for monitoring the
clinical status of thyroid cancer. Further investigations
are required to clarify the role of oxidative stress in the
thyroid carcinogenesis. These results may shed light
on the development of novel methods to distinguish
thyroid cancer patients from disease controls and/or
healthy controls.
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